11/15
02:34 am
ptn
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ... [Yahoo! Finance]
High
Report
Palatin Technologies Inc (PTN) Q1 2025 Earnings Call Highlights: Strategic Shifts Amid Revenue ... [Yahoo! Finance]
11/14
07:39 am
ptn
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results [Yahoo! Finance]
High
Report
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results [Yahoo! Finance]
11/14
07:30 am
ptn
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
Medium
Report
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
11/8
09:57 am
ptn
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
High
Report
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
11/4
07:30 am
ptn
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
Medium
Report
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
10/31
07:30 am
ptn
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
Medium
Report
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
10/24
07:30 am
ptn
Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium
Low
Report
Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium
10/23
07:30 am
ptn
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
Low
Report
Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
10/7
04:24 pm
ptn
Palatin Receives Notice of Non-Compliance from NYSE American [Yahoo! Finance]
Low
Report
Palatin Receives Notice of Non-Compliance from NYSE American [Yahoo! Finance]
10/7
04:15 pm
ptn
Palatin Receives Notice of Non-Compliance from NYSE American
Medium
Report
Palatin Receives Notice of Non-Compliance from NYSE American
10/1
07:33 am
ptn
Palatin Technologies GAAP EPS of -$0.51 [Seeking Alpha]
Medium
Report
Palatin Technologies GAAP EPS of -$0.51 [Seeking Alpha]
10/1
07:30 am
ptn
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
Medium
Report
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
9/30
06:22 pm
ptn
Here's the major earnings before the open tomorrow [Seeking Alpha]
Medium
Report
Here's the major earnings before the open tomorrow [Seeking Alpha]
9/26
07:30 am
ptn
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results
Low
Report
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results
9/9
07:30 am
ptn
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
Low
Report
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
8/28
07:30 am
ptn
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)
Medium
Report
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)
8/23
05:36 am
ptn
Palatin Technologies doses first subject in Phase II obesity treatment trial [Yahoo! Finance]
Low
Report
Palatin Technologies doses first subject in Phase II obesity treatment trial [Yahoo! Finance]